Main pathways of tyrosine kinase inhibitor (TKI) resistance in chronic myeloid leukemia (CML), distinguishing between BCR::ABL1-dependent and independent mechanisms. The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.